Drugs / Pizuglanstat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04825431 | Mar → Jun 2021 | — | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pizuglanstat | “Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor and investigational treatment for Duchenne muscular dystrophy.” PMID 39840517 ↗ Jan 2025 |
| Action | Inhibit | “Pizuglanstat is a novel hematopoietic prostaglandin D synthase inhibitor” PMID 39840517 ↗ Jan 2025 |
| Route | Oral | “single oral administration under fasted conditions on day 1” NCT04825431 ↗ |